logo
Plus   Neg
Share
Email

Genentech: Phase III PEMPHIX Study With Rituxan Meets Primary End Point

Genentech, affiliated to Swiss drug major Roche Group (RHHBY), announced Thursday that the Phase III PEMPHIX Study with Rituxan (Rituximab) in patients with Pemphigus Vulgaris or PV met the primary and secondary endpoints.

The study evaluated the efficacy and safety of Rituxan compared to mycophenolate mofetil or MMF that is accepted as standard of care.

Rituxan demonstrated that it is superior to standard of care in achieving sustained remission in adults with moderate to severe PV.

Genentech will present the complete data from the PEMPHIX study at an upcoming medical congress. The results will be submited to health authorities around the world, including the U.S. Food and Drug Administration.

In June 2018, Rituxan became the first and only biologic therapy approved by the FDA for the treatment of PV based on results from the Ritux 3 clinical trial. The latest PEMPHIX trial provided additional clinical evidence on the effectiveness of Rituxan for PV.

PV is a rare, serious and potentially life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apotex Corp. recalled all lots of type 2 diabetes medication Metformin hydrochloride in the form of oral film-coated tablets for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Groupe Renault plans to cut about 14,600 jobs across the world and lower its production capacity. The plan includes almost 4,600 jobs reduction in France, through voluntary retirement and retraining. Amazon said it will convert 125,000 of the 175,000 temporary workers it hired in March amid the coronavirus pandemic, to permanent full-time employees in June. The e-commerce giant had hired the temporary employees in March to meet strong consumer demand amid the lockdown. The job openings were in Amazon's fulfillment centers and its delivery network.
Follow RTT